Ruiz-Saenz A - Search Results

1

Targeting of HER/ErbB family proteins using broad spectrum Sec61 inhibitors coibamide A and apratoxin A.

Kazemi S, Kawaguchi S, Badr CE, Mattos DR, Ruiz-Saenz A, Serrill JD, Moasser MM, Dolan BP, Paavilainen VO, Oishi S, McPhail KL, Ishmael JE. Kazemi S, et al. Among authors: ruiz saenz a. Biochem Pharmacol. 2021 Jan;183:114317. doi: 10.1016/j.bcp.2020.114317. Epub 2020 Nov 3. Biochem Pharmacol. 2021. PMID: 33152346 Free PMC article.

2

Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum.

Ruiz-Saenz A, Sandhu M, Carrasco Y, Maglathlin RL, Taunton J, Moasser MM. Ruiz-Saenz A, et al. Oncogene. 2015 Oct 8;34(41):5288-94. doi: 10.1038/onc.2014.455. Epub 2015 Jan 26. Oncogene. 2015. PMID: 25619841 Free PMC article.

3

Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib.

Amin DN, Ruiz-Saenz A, Gulizia N, Moasser MM. Amin DN, et al. Oncotarget. 2015 Dec 1;6(38):41123-33. doi: 10.18632/oncotarget.5660. Oncotarget. 2015. PMID: 26516700 Free PMC article.

4

Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin.

Campbell MR, Zhang H, Ziaee S, Ruiz-Saenz A, Gulizia N, Oeffinger J, Amin DN, Ahuja D, Moasser MM, Park CC. Campbell MR, et al. Breast Cancer Res Treat. 2016 Feb;155(3):431-40. doi: 10.1007/s10549-016-3698-y. Epub 2016 Feb 9. Breast Cancer Res Treat. 2016. PMID: 26860947 Free PMC article.

5

Targeting HER2 by Combination Therapies.

Ruiz-Saenz A, Moasser MM. Ruiz-Saenz A, et al. J Clin Oncol. 2018 Mar 10;36(8):808-811. doi: 10.1200/JCO.2017.77.1899. Epub 2018 Jan 30. J Clin Oncol. 2018. PMID: 29381433 Free PMC article. No abstract available.

6

HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3.

Ruiz-Saenz A, Dreyer C, Campbell MR, Steri V, Gulizia N, Moasser MM. Ruiz-Saenz A, et al. Cancer Res. 2018 Jul 1;78(13):3645-3658. doi: 10.1158/0008-5472.CAN-18-0430. Epub 2018 May 14. Cancer Res. 2018. PMID: 29760043 Free PMC article.

7

A Dimerization Function in the Intrinsically Disordered N-Terminal Region of Src.

Spassov DS, Ruiz-Saenz A, Piple A, Moasser MM. Spassov DS, et al. Among authors: ruiz saenz a. Cell Rep. 2018 Oct 9;25(2):449-463.e4. doi: 10.1016/j.celrep.2018.09.035. Cell Rep. 2018. PMID: 30304684 Free PMC article.

8

Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities.

Coppé JP, Mori M, Pan B, Yau C, Wolf DM, Ruiz-Saenz A, Brunen D, Prahallad A, Cornelissen-Steijger P, Kemper K, Posch C, Wang C, Dreyer CA, Krijgsman O, Lee PRE, Chen Z, Peeper DS, Moasser MM, Bernards R, van 't Veer LJ. Coppé JP, et al. Among authors: ruiz saenz a. Nat Cell Biol. 2019 Jun;21(6):778-790. doi: 10.1038/s41556-019-0328-z. Epub 2019 Jun 3. Nat Cell Biol. 2019. PMID: 31160710 Free PMC article.

9

Proteomic Analysis of Src Family Kinase Phosphorylation States in Cancer Cells Suggests Deregulation of the Unique Domain.

Ruiz-Saenz A, Zahedi F, Peterson E, Yoo A, Dreyer CA, Spassov DS, Oses-Prieto J, Burlingame A, Moasser MM. Ruiz-Saenz A, et al. Mol Cancer Res. 2021 Jun;19(6):957-967. doi: 10.1158/1541-7786.MCR-20-0825. Epub 2021 Mar 16. Mol Cancer Res. 2021. PMID: 33727342 Free PMC article.

10

Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers.

Campbell MR, Ruiz-Saenz A, Peterson E, Agnew C, Ayaz P, Garfinkle S, Littlefield P, Steri V, Oeffinger J, Sampang M, Shan Y, Shaw DE, Jura N, Moasser MM. Campbell MR, et al. Among authors: ruiz saenz a. Cell Rep. 2022 Feb 1;38(5):110291. doi: 10.1016/j.celrep.2021.110291. Cell Rep. 2022. PMID: 35108525 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

20 results

Search Page